🟢 GT Biopharma is trading 7.1% up in pre-market

GT Biopharma is trading 7.1% up at $0.30 in pre-market after rebounding from its August 17, 2026 close of $0.28.

• No fresh company-specific announcement directly explaining the move was identified.
• Its August 14, 2026 second-quarter report cited approximately $5.1 million in cash, ongoing clinical-trial enrollment, and expected second-half pipeline updates.
• The broader market is weaker, so global sentiment does not clearly explain the gain.